Development and in vitro evaluation of tablets based on the antichagasic benznidazole

This work aimed to verify the interferences caused by the use of excipients for immediate release tablets based on benznidazole obtained by direct compression and the accomplishment of a comparative study between the tablets developed and the reference medicine RochaganTM, obtained by wet granulatio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revista brasileira de ciências farmacêuticas 2008-09, Vol.44 (3), p.383-389
Hauptverfasser: Soares Sobrinho, José Lamartine, Lima, Luciana Neiva Antunes, Perrelli, Diego Cavalcanti, Silva, Jeckson Luiz da, Medeiros, Flávia Patrícia Morais de, Soares, Mônica Felts de La Roca, Rolim Neto, Pedro José
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This work aimed to verify the interferences caused by the use of excipients for immediate release tablets based on benznidazole obtained by direct compression and the accomplishment of a comparative study between the tablets developed and the reference medicine RochaganTM, obtained by wet granulation. Seven small-scale batches (SSB) were developed and aspects such as compressibility, powder flow, mean weight, friability, disintegration, hardness, assay, content uniformity, kinetic of release in vitro (dissolution) and drug/excipients physical-chemical compatibility were evaluated. Based on the obtained results it can be verified that the analyzed powders presented adequated characteristics for the direct compression process, beyond the inexistent evidence of a physical-chemical interaction between the drug and the tested excipients. The tablets obtained from SSB I and III were chosen for the comparative study with the reference medicine, demonstrating similarity with the statistically treated obtained results, becoming an alternative option of a medicine product for the treatment of Chagas' disease with reduced cost and satisfactory quality.
ISSN:1516-9332
1516-9332
DOI:10.1590/S1516-93322008000300007